The spatial transcriptomics of EGFR-mutant non-small cell lung cancer before osimertinib treatment

EGFR-mutant non-small cell lung cancer (NSCLC) is commonly treated with EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib. However, the development of resistance remains a major clinical challenge, with various resistance mechanisms having been identified. Emerging evidence suggests that the tumor microenvironment (TME) may contribute to this resistance. In this study, we analyzed the TME of pre-treatment tumor samples from EGFR-mutant NSCLC patients using the Visium HD spatial transcriptomics platform to explore its potential role in the development of resistance.